Harrow Health (HROW)
NASDAQ:HROW
Want to see HROW full AI Analyst Report?
HROW Stock Chart & Stats
$41.50
-$0.36(-1.00%)
At close: 4:00 PM EST
$41.50
-$0.36(-1.00%)
Day’s Range― - ―
52-Week Range$27.76 - $54.85
Previous CloseN/A
Volume51.77K
Average Volume (3M)880.54K
Market Cap
$1.22B
Enterprise Value$1.52B
Total Cash (Recent Filing)$94.64M
Total Debt (Recent Filing)$300.67M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Aug 11, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding37,275,110
10 Day Avg. Volume785,430
30 Day Avg. Volume880,539
Financial Highlights & Ratios
PEG Ratio4.91
Price to Book (P/B)34.35
Price to Sales (P/S)6.61
P/FCF Ratio41.91
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue5.65
Enterprise Value/Gross Profit7.63
Enterprise Value/Ebitda38.03
Forecast
1Y Price Target
$67.17Price Target Upside61.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.3
Revenue Forecast (FY)$348.48M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsSustained gross margins near 74–75% indicate advantaged product economics in ophthalmics. High product-level margin provides structural profitability potential as volumes scale, supports reinvestment in commercialization and R&D, and cushions the business against some pricing and reimbursement pressure.
Improving Cash GenerationA return to positive operating and free cash flow represents a durable improvement in cash conversion versus earlier losses. Positive cash flow reduces near-term reliance on equity raises, helps fund launches and working capital, and supports deleveraging or targeted organic investment if sustained.
Commercial Momentum & ScaleMeaningful prescription growth, market‑share gains and a larger, specialized salesforce indicate durable demand and better conversion capacity. Repeatable adoption (VEVYE, IHEEZO, TRIESENCE) plus commercial scale raise odds of sustained revenue growth and improved pricing power over the medium term.
Bears Say
Very High LeverageDebt-to-equity near 10.5x reflects a heavily leveraged capital structure that materially increases financial risk. High leverage raises interest expense, reduces strategic flexibility for M&A or R&D, and heightens refinancing and covenant sensitivity, constraining long-term operational optionality.
Persistent Net LossesOngoing net losses and negative returns on equity limit the ability to rebuild shareholder equity and retained earnings. Even with operational improvements, sustained losses necessitate external funding and weaken resilience to shocks, raising the cost and frequency of financing over time.
Revenue Volatility & Gross-to-Net RiskMaterial gross-to-net adjustments and channel timing (the $8M VEVYE hit) reveal structural exposure to payor mix and reporting lags. Such dynamics can depress reported revenue and net pricing unpredictably, complicating forecasting and undermining sustainable margin capture despite strong underlying demand.
Harrow Health News
HROW FAQ
What was Harrow Health’s price range in the past 12 months?
Harrow Health lowest stock price was $27.75 and its highest was $54.85 in the past 12 months.
What is Harrow Health’s market cap?
Harrow Health’s market cap is $1.22B.
When is Harrow Health’s upcoming earnings report date?
Harrow Health’s upcoming earnings report date is Aug 11, 2026 which is in 69 days.
How were Harrow Health’s earnings last quarter?
Harrow Health released its earnings results on May 11, 2026. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.399 by -$0.341.
Is Harrow Health overvalued?
According to Wall Street analysts Harrow Health’s price is currently Undervalued.
Does Harrow Health pay dividends?
Harrow Health does not currently pay dividends.
What is Harrow Health’s EPS estimate?
Harrow Health’s EPS estimate is -0.17.
How many shares outstanding does Harrow Health have?
Harrow Health has 37,275,110 shares outstanding.
What happened to Harrow Health’s price movement after its last earnings report?
Harrow Health reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.399. Following the earnings report the stock price went down -23.686%.
Which hedge fund is a major shareholder of Harrow Health?
Currently, no hedge funds are holding shares in HROW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harrow Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.17 (61.85% Upside)
$67.17 (61.85% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 682.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.60%
12-Months-Change
Fundamentals
Return on Equity
-33.65%
Trailing 12-Months
Asset Growth
15.21%
Trailing 12-Months
Company Description
Harrow Health
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
HROW Company Deck
HROW Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized consistently strong and accelerating demand across Harrow's core commercial products (VEVYE, IHEEZO, TRIESENCE), successful commercial investments (significant salesforce expansion), operational recoveries (Access+), multiple upcoming catalysts (multiunit packaging, clinical data, BYOOVIZ/BYQLOVI launches, IOPIDINE J-code) and reaffirmed full-year guidance. The principal near-term negative was a discrete $8M VEVYE gross-to-net revenue reduction driven by an unexpected high-deductible patient mix and reporting lags, plus a negative adjusted EBITDA in Q1 and some channel inventory timing for IHEEZO. Management identified and implemented corrective actions and expects sequential improvement beginning in Q2 and stronger performance in H2 2026. Overall, positives around demand, market share gains, commercial scale and pipeline progress substantially outweigh the discrete operational and timing headwinds.View all HROW earnings summariesHROW Stock 12 Month Forecast
Average Price Target
$67.17
▲(61.85% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Ownership Overview
20.11% Insiders
9.78% Mutual Funds
24.26% Other Institutional Investors
34.42% Public Companies and Individual Investors